Dupilumab Effective for Severe Atopic Dermatitis at 5 Years: Daily Dose
Your daily dose of the clinical news you may have missed.
When is It Time to Refer? A Dermatologist Considers Atopic Dermatitis Treated in Primary Care
Up to 80% of atopic dermatitis is managed in primary care but some patients will need a higher level of care. Dr Mona Shahriari discusses factors that point to referral.
Nonsteroidal Topical Treatments for Eczema: A Product Snapshot with Mona Shahriari, MD
They are a Janus kinase (JAK)1/JAK2 inhibitor, a phosphodiesterase-4 inhibitor, and an investigational aryl hydrocarbon receptor agonist. Learn more about each.
New Phase 3 Trials Investigate Survodutide as a Promising Treatment for Obesity
SYNCHRONIZE-1 and -2 will provide "robust evidence" on the safety, efficacy, and tolerability of survodutide in adults with obesity with or without T2D.
Agitation-Type Behavior Occurs Across the Spectrum of Alzheimer Disease Severity, Advises Expert
Agitation in Alzheimer disease is not limited to the later stages, geriatric psychiatrist George Grossberg, MD, explains; look for it across the spectrum.
FIT Completion Rates Back Screening for CRC at Age 45: Daily Dose
FDA Pushes Back PDUFA Date 3 Months for Tapinarof, 1% Cream for Atopic Dermatitis in Adults and Children
The standard 3-month extension is required by the FDA to review what it considered a "major amendment" to the Organon sNDA, ie, new data from ADORING 3.
Agitation in Alzheimer Disease: A Behavioral Snapshot with Geriatric Psychiatrist George Grossberg, MD
Agitation is the most common disabling neuropsychiatric symptom experienced by individuals with Alzheimer dementia; Grossberg explains how common in this short interview.
Semaglutide May Reduce Alzheimer’s Risk in Adults with T2D: Daily Dose
The Most Common Bleeding Disorder in Your Patients Could be Hiding in Plain Sight
von Willebrand disease affects up to 1% of the population yet diagnosis is delayed an average of 16 years after onset of symptoms, especially in women.
Semaglutide 2.4 mg Reduces Risk for Hospitalization for Any Cause in Adults with CVD, Obesity
ObesityWeek 2024. Semaglutide 2.4 mg reduces rates of composite CV outcomes in high-risk patients without diabetes and now is shown to reduce inpatient care and length of stay.
ObesityWeek 2024: Viking Therapeutics Presents New Positive Data from VK2735 Obesity Program
Results from the VENTURE phase 2 trial and a phase I oral formulation study found that VK2735, a dual GLP-1 and GIP receptor agonist, demonstrated promise in treating obesity.
Semaglutide 2.4 mg: Shows Superior Improvement in Liver Fibrosis, MASH Resolution in Pivotal Phase 3 Trial
Novo Nordisk announced the topline findings from the pivotal ESSENCE trial and intends to file applications in early 2025 with US and EU regulators.
The RSV Vaccine Population was Narrowed for Good Reason, says Robert Hopkins, Jr, MD, Medical Director of the NFID
ACIP recommendations for the most appropriate older population for the RSV vaccine has shifted and the NFID medical director explains why.
Metabolic Bariatric Surgery Takes a Backseat as GLP-1RA Use Soars, According to New Research
Clinicians should continue to monitor trade-offs between pharmacologic and surgical management of obesity, researchers said.
FDA Approves New Treatment for Uncomplicated UTIs: Daily Dose
GoodRx, Opill Team Up on OTC Delivery Program for Contraceptive
The new e-commerce partnership expands access to Opill by allowing direct delivery of the contraceptive to consumers' homes without a prescription.
Eisai Announces Completion of Rolling BLA for SQ Autoinjector-Delivered Lecanemab
The autoinjector delivers a weekly maintenance dose of 360 mg lecanemab for individuals who have completed biweekly treatment initiation by IV infusion.
Sotagliflozin Setback: Cautionary FDA AdComm Vote Reflects Continued Concern for Negative Risk/Benefit Ratio in T1D with CKD
The FDA's Endocrinologic and Metabolic Drugs Advisory Committee voted 11 to 3 against recommending the SGLT1/SLGT2 inhibitor to treat adults with T1D and CKD.
Dermatologist Mona Shahriari, MD, Talks Nonsteroidal Topicals for Atopic Dermatitis
There are 3 classes of nonsteroidal topical therapies for atopic dermatitis that target the specific underlying pathophysiology of the skin disease. Shahriari provides a primer.
